|
|
| | Carbamic acid, N-[(1S)-1-[[[(1S)-1-formyl-2-[(3S)-2-oxo-3-pyrrolidinyl]ethyl]amino]carbonyl]-3-methylbutyl]-, phenylmethyl ester Basic information |
| | Carbamic acid, N-[(1S)-1-[[[(1S)-1-formyl-2-[(3S)-2-oxo-3-pyrrolidinyl]ethyl]amino]carbonyl]-3-methylbutyl]-, phenylmethyl ester Chemical Properties |
| Boiling point | 680.6±50.0 °C(Predicted) | | density | 1.170±0.06 g/cm3(Predicted) | | pka | 11.13±0.46(Predicted) |
| | Carbamic acid, N-[(1S)-1-[[[(1S)-1-formyl-2-[(3S)-2-oxo-3-pyrrolidinyl]ethyl]amino]carbonyl]-3-methylbutyl]-, phenylmethyl ester Usage And Synthesis |
| Description | GC373 is a novel broad-spectrum antiviral against 3c or 3c-like proteases of picornaviruses, noroviruses, and coronaviruses | | Uses | GC373 is a potent inhibitor of SARS-CoV-2 Mpro that blocks virus replication with an IC50 of 0.4 μM. CG373 can be utilized in anti-COVID-19 research[1]. | | References | [1] Vuong W, et al. Improved SARS-CoV-2 Mpro inhibitors based on feline antiviral drug GC376: Structural enhancements, increased solubility, and micellar studies. Eur J Med Chem. 2021 Oct 15;222:113584. DOI:10.1016/j.ejmech.2021.113584 |
| | Carbamic acid, N-[(1S)-1-[[[(1S)-1-formyl-2-[(3S)-2-oxo-3-pyrrolidinyl]ethyl]amino]carbonyl]-3-methylbutyl]-, phenylmethyl ester Preparation Products And Raw materials |
|